Blanket contracts in jeopardy

WASHINGTON - Controversy over the Scripps-Sandoz technology transfer agreement is likely to stimulate regulations to limit the scope and duration of collaborations between NIH grantees and private industry, according to an NIH official.

The Scripps Research Institute deal with Sandoz Pharmaceuticals Corp. violates the intent of federal technology transfer policy but probably is not illegal, said the official, who spoke on condition of anonymity...